tiprankstipranks
Advertisement

IDYN - ETF AI Analysis

Compare

Top Page

IDYN

iShares International Equity Factor Rotation Active ETF (IDYN)

Rating:65Neutral
Price Target:
IDYN, the iShares International Equity Factor Rotation Active ETF, has a solid overall rating driven largely by high-quality holdings like Novartis and AstraZeneca, which benefit from strong financial performance, positive earnings outlooks, and healthy long-term growth prospects. ASML and Vinci also support the fund’s quality through robust profitability and generally favorable trends, while some holdings such as Assicurazioni Generali and Enel are more mixed due to debt and momentum challenges. A key risk factor is that several major positions share issues like high valuations or weaker technical momentum, which could increase volatility if market conditions turn.
Positive Factors
Strong Leading Holdings
Several of the largest positions, such as ASML, Novartis, and Deutsche Telekom, have shown strong or steady gains, helping support the ETF’s overall results.
Broad International Diversification
The fund spreads its investments across many countries in Europe and Asia, which can reduce the impact of weakness in any single market.
Balanced Sector Mix
Holdings are spread across industrials, financials, health care, communication services, and other sectors, limiting reliance on one part of the economy.
Negative Factors
Recent Short-Term Weakness
The ETF has experienced a weak recent month even though longer-term performance has been more positive, which may signal near-term volatility.
Moderate Expense Ratio
The fund’s fee is higher than many simple index ETFs, which can slightly reduce net returns over time for buy-and-hold investors.
Exposure to Lagging Financial Names
Some financial holdings like Banco Santander and Assicurazioni Generali have been weak, which can drag on performance if this trend continues.

IDYN vs. SPDR S&P 500 ETF (SPY)

IDYN Summary

The iShares International Equity Factor Rotation Active ETF (IDYN) is an actively managed fund that invests in large and mid-sized companies outside the U.S., following a total international market theme rather than a fixed index. It holds well-known global names like ASML Holding and Novartis, and spreads money across many countries such as Japan, the UK, and Germany, as well as some emerging markets. Someone might invest in IDYN for broad international diversification and the potential for growth overseas. A key risk is that international and emerging market stocks can be volatile and may go up or down more than U.S. stocks.
How much will it cost me?This ETF has an expense ratio of 0.45%, which means you’ll pay about $4.50 per year for every $1,000 you invest. That’s higher than the cost of many simple index ETFs because this fund is actively managed and uses a factor-rotation strategy that requires more research and trading.
What would affect this ETF?This ETF could benefit if international economic growth improves, especially in Europe and other markets outside the U.S., boosting industrial, financial, and healthcare companies like ASML, Novartis, and AstraZeneca, and if global stock markets reward the fund’s flexible, factor-based strategy. On the other hand, it could be hurt by slower growth or financial stress in non-U.S. economies, rising interest rates that pressure banks and utilities, energy or regulatory shocks affecting companies like Enel and Siemens Energy, or if its active rotation strategy picks factors that fall out of favor.

IDYN Top 10 Holdings

IDYN’s story is being written mostly in Europe, with heavy exposure to industrials, financials, and health care outside the U.S. ASML is the clear engine here, rising steadily and giving the fund a strong tech-and-semiconductor tilt despite its small sector weight. Defensive health care names like Novartis are holding up reasonably well, while AstraZeneca has been more mixed, losing a bit of steam lately. On the flip side, European financials such as Banco Santander and insurers like Generali have been lagging, acting as a mild drag on overall performance.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV3.71%$3.98M€471.67B116.01%
76
Outperform
Novartis AG2.96%$3.17MCHF223.05B44.23%
80
Outperform
AstraZeneca2.89%$3.10M$318.08B52.48%
80
Outperform
Deutsche Telekom1.79%$1.91M€152.93B-0.50%
67
Neutral
Banco Santander1.71%$1.84M€151.84B83.96%
73
Outperform
Siemens Energy1.70%$1.83M€140.19B204.59%
72
Outperform
Assicurazioni Generali S.p.A.1.70%$1.82M€55.92B20.79%
63
Neutral
Enel S.p.A.1.67%$1.79M€100.31B41.27%
67
Neutral
Vinci SA1.56%$1.67M€76.41B22.11%
76
Outperform
1.49%$1.60M

IDYN Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
30.02
Positive
100DMA
29.07
Positive
200DMA
Market Momentum
MACD
0.01
Negative
RSI
60.19
Neutral
STOCH
83.62
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDYN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 28.97, equal to the 50-day MA of 30.02, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 60.19 is Neutral, neither overbought nor oversold. The STOCH value of 83.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYN.

IDYN Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$107.52M0.45%
65
Neutral
$999.94M0.45%
64
Neutral
$928.61M0.59%
67
Neutral
$490.80M0.55%
71
Outperform
$273.43M0.30%
59
Neutral
$268.93M0.60%
61
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IDYN
iShares International Equity Factor Rotation Active ETF
30.50
4.97
19.47%
APIE
ActivePassive International Equity ETF
MFSI
MFS Active International ETF
OSEA
Harbor International Compounders ETF
AVDS
Avantis International Small Cap Equity ETF
QLTI
GMO International Quality ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement